Chronic exposure of human mesangial cells to high glucose environments activates the p38 MAPK pathway  by Wilmer, William A. et al.
Kidney International, Vol. 60 (2001), pp. 858–871
Chronic exposure of human mesangial cells to high glucose
environments activates the p38 MAPK pathway
WILLIAM A. WILMER, CYNTHIA L. DIXON, and COURTNEY HEBERT
Nephrology Division, Department of Internal Medicine, Heart Lung Research Institute, The Ohio State University College of
Medicine, Columbus, Ohio, USA
MAPK in HMCs grown seven days in HG was demonstratedChronic exposure of human mesangial cells to high glucose
by increased tyrosine and threonine phosphorylation of p38environments activates the p38 MAPK pathway.
MAPK proteins and increased kinase activity of immunopre-Background. High glucose (HG) environments activate sev-
cipitated p38 MAPK. As assessed by a kinase assay, p38 MAPKeral protein kinase pathways in mesangial cells, including the
activity in cells grown in HG for seven days exceeded that ofmitogen-activated protein kinase (MAPK) pathway, ERK. The
NG cells by more than 250%. This difference was not due top38 MAPK pathway is activated by events that occur in the
differences in the amount of p38 MAPK protein between thesetting of diabetes, such as protein kinase C (PKC) up-regula-
treatment groups. Acute osmotic activation of p38 MAPK oc-tion and cellular stresses (osmotic stress and redox changes).
curred at extremely high mannitol concentrations (250 mOsm/L)Substrates of activated p38 MAPK include transcription factors
that exceeded the osmotic stress of acute HG. Furthermore,that are involved in the microvascular complications of diabe-
in cells grown for seven days in mannitol at concentrationstes. This current study investigated the mechanisms of HG-
similar to HG, p38 MAPK activity was similar to control values.mediated activation of p38 MAPK in cultured human mesan-
Phorbol ester (PMA) treatment stimulated a twofold increasegial cells (HMCs) and the effects of p38 MAPK activation on
in p38 MAPK activity. The addition of GFX or Ro 32-0432 tothe transcription factor activator protein-1 (AP-1).
HG cells, at concentrations that inhibited PMA activation ofMethods. HMCs were cultured in 5 mmol/L d-glucose [nor-
p38 MAPK, did not inhibit the glucose-mediated p38 MAPKmal glucose (NG)] or 30 mmol/L d-glucose (HG) for seven
activation. Rottlerin, a PKC  inhibitor, also failed to reversedays. Cells were also treated with HG for brief periods of time
the HG-mediated p38 MAPK activation. Treatment of HG cells(0.5 to 4 hours) to assess the acute effects of HG on p38 MAPK.
with L-NAC or DPI inhibited the HG-mediated p38 MAPKUsing Western blotting of HMC lysates, changes in the tyrosine
phosphorylation. As we have previously shown, DNA bindingand threonine phosphorylation of p38 MAPK were measured.
of the transcription factor complex AP-1 was increased in HGThe kinase activity of immunoprecipitated p38 MAPK was
cells. This binding was reversed by treatment of the HG cellsdetermined by an in vitro assay that measured the phosphoryla-
with the p38 MAPK inhibitor SB 203580.tion and activation of MAPKAP kinase-2, an intermediary
Conclusions. Chronic exposure of HMC to HG concentra-signaling protein downstream of p38 MAPK. To investigate
tions activates the p38 MAPK pathway. This activation appearsthe role of osmotic stress in HG activation of p38 MAPK, cells
to be independent of changes in the amount of total p38 MAPKwere acutely treated with mannitol (25 to 250 mOsm/L  5 to
produced by the cells, independent of chronic osmotic stress60 min) or were grown seven days in media supplemented
and independent of PKC activation. The reversal of p38 MAPKwith mannitol at concentrations iso-osmotic to HG media. To
by L-NAC and DPI suggests the glucose-mediated p38 MAPKinvestigate the role of PKC in HG-mediated p38 MAPK activa-
activation may occur via reactive oxygen species. The activitytion, HMCs were treated with the PKC inhibitors GF 109203X,
of AP-1, a transcription factor complex that regulates severalRo 32-0432, or rottlerin during the last several hours of HG
genes involved in diabetic nephropathy, is reversed when thetreatment. HG conditioned cells were also treated with the anti-
p38 MAPK pathway is inhibited. These findings suggest theoxidants L-N-acetylcysteine (L-NAC) or diphenyliodonium
p38 MAPK pathway may be an important pathway involved(DPI) prior to harvest. To determine a functional significance
in diabetic complications.of HG-mediated p38 MAPK activation, the DNA binding of
the transcription factor complex AP-1 was measured by elec-
trophoretic mobility shift assay.
Results. The p38 MAPK pathway was not activated by the Several clinical studies have demonstrated that ele-
acute addition of HG to the HMCs. However, activation of p38 vated blood glucose levels are a risk for the development
of microvascular complications of diabetes, including di-
abetic nephropathy [1–4]. During the development ofKey words: diabetes, osmotic stress, protein kinase C, reactive oxygen
species, activator protein-1, mitogen-activated protein kinase. diabetic nephropathy, genes that alter cell growth and
extracellular matrix (ECM) protein production are ex-Received for publication April 3, 2000
pressed differently than in the euglycemic setting. Muchand in revised form February 21, 2001
Accepted for publication March 16, 2001 of this altered gene expression is the result of glucose-
mediated activation of cell signaling pathways [5–7]. In 2001 by the International Society of Nephrology
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a variety of cells, high glucose (HG) concentrations up- in models of inflammation, mRNAs of adhesion proteins
and interleukins are stabilized by activated p38 MAPKregulate serine–threonine protein kinases, including sev-
eral isoforms of the protein kinase C (PKC) pathway, and [43–46].
That p38 MAPK can be activated by osmotic stress,the mitogen-activated protein kinase (MAPK) pathway,
ERK [8–13]. PKC activation, or reactive oxygen species (ROS) sug-
gests that this pathway may be an important signalingThe ERK pathway is one of four MAPK pathways
that also include the Jun N-terminal kinases (JNKs), p38 pathway in the development of diabetic complications.
In rat aortic smooth muscle cells, HG concentrationsMAPKs, and the recently discovered Big MAPK pathway.
These MAPK pathways regulate many transcription fac- activate the p38 MAPK pathway in a PKC-dependent
and osmotic stress-dependent manner [14]. Based ontors that control cell growth and ECM gene expression.
Therefore, MAPKs are possible mediators of diabetic these observations and evidence that genes that are p38
MAPK-dependent are expressed in diabetes [47], wecomplications. Haneda et al first demonstrated a modest
level of ERK pathway activation in mesangial cells grown hypothesized that HG concentrations could activate p38
MAPK in human mesangial cells (HMCs). Our currentin HG environments [13]. Since then, the p38 MAPK
pathway has also been shown to be inducible by HG report shows that chronic HG exposure stimulates p38
MAPK activity in HMCs. However, this p38 MAPKenvironments in vascular smooth muscle cells (VSMCs),
pancreatic islet cells, and rat mesangial cells [14–17]. activation is independent of PKC activation and inde-
pendent of osmotic stress. A role for ROS in the glucose-In contrast, we and others have reported that the JNK
pathway is not inducible by HG concentrations in human mediated p38 MAPK activation is suggested by the re-
versal of p38 MAPK phosphorylation by antioxidantor rat mesangial cells [16, 18]. This difference in glucose
responsiveness between the MAPK pathways may be compounds. In these studies, we also show that glucose-
mediated binding of activator protein-1 (AP-1), a tran-due to differences in the mode of activation of each
pathway. ERKs are activated by growth factors and other scription factor that regulates many ECM genes, is re-
versed by p38 MAPK inhibition.mitogens that up-regulate PKC. In Haneda et al’s report,
PKC activation was an intermediate step in the glucose-
mediated activation of ERK [13]. In contrast, the JNK
METHODS
pathway is classically PKC independent in its stimulation
Human mesangial cell culture and conditioningby cell stress (osmotic stress, redox changes, pH shifts,
or temperature changes) and pro-inflammatory cytokines Human mesangial cells were isolated from cadaver
kidneys deemed anatomically unsuitable for use in trans-[19–21]. The p38 MAPK pathway is uniquely activated
by agonists that stimulate both the ERK and JNK path- plantation. Glomeruli were isolated from the renal cortex
by mincing the tissue and then passing the tissue fragmentsways. p38 MAPK proteins are activated by cell stress
[22–28] and by growth factors, cytokines, and other mito- through progressively smaller sieves (Bellco Glass Inc.,
Vineland, NJ, USA). Thereafter, the HMCs were charac-gens, including those that increase PKC activity [29–31].
When activated, the p38 MAPK proteins alter cellular terized as described [48–50]. In these studies, HMCs
from at least three donors were used between passagesfunctions at transciptional and post-transcriptional levels.
p38 MAPK regulates the phosphorylation and activation 5 and 7. The HMCs were cultured on plasticware for
seven days at 37C, 5% CO2 in Media 199 (Life Sciences,of several transcription factors (ATF2, CREB, CHOP,
Elk-1, MEF2C) [32–35] that modulate a variety of genes, Grand Island, NY, USA) containing 10% heat-inacti-
vated fetal calf serum, 50 U/mL penicillin, and 50 mg/mLincluding genes involved in cell growth and ECM expres-
sion. Cell contractility is also regulated by p38 MAPK streptomycin (Sigma Chemicals, St. Louis, MO, USA)
without supplemental d-glucose [5 mmol/L d-glucose, orthrough the phosphorylation of small heat shock proteins
[36–38]. p38 MAPK regulation of some transcription normal glucose (NG)] or in media supplemented with
25 mmol/L d-glucose (Sigma) for a total d-glucose concen-factors and cell contractility occurs via intermediary sig-
naling proteins, such as the MAPKAP kinases [29, 36, tration of 30 mmol/L (HG). Media were changed every
three days after cell passage. In parallel experiments,37, 39–41]. The p38 MAPK proteins also regulate gene
transcription independently of transcription factor acti- NG cells were treated with HG for 30 minutes to four
hours prior to harvest. To evaluate the role of osmoticvation. For example, we previously reported that inter-
leukin-1 (IL-1)–induced expression of the monocyte stress in p38 MAPK activation, cells were first placed in
serum-free NG media [Media 199 0.25% bovine serumchemoattractant protein-1 (MCP-1) gene requires p38
MAPK, although DNA binding of the transcription fac- albumin (BSA)] for 18 hours and treated for 5 to 60
minutes with increasing concentrations of mannitol (25 totor responsible for MCP-1 expression, nuclear factor-B,
is unaffected by p38 MAPK inhibition [42]. Other inves- 250 mOsm/L). HMCs were also grown for seven days in
serum-containing NG media supplemented with manni-tigators have shown that p38 MAPK influences transcrip-
tion through the stabilization of mRNA. For example, tol (Sigma) at a concentration iso-osmolar to HG media.
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To investigate the role of PKC activation on the p38 27C. The nitrocellulose was washed in PBST then incu-
bated with appropriate biotinylated secondary antibod-MAPK pathway, HMCs were treated with the phorbol
ester phorbol 12-myristate 13-acetate (PMA; 10 to 50 ies (Zymed Laboratories, Inc., South San Francisco, CA,
USA) and streptavidin-horseradish peroxidase. Bandsnmol/L; Sigma) for 30 minutes. To determine the role
of PKC in HG activation of p38 MAPK, NG and HG of interest were demonstrated using an enhanced chemi-
luminescence (ECL) technique (Amersham, Inc., Arling-cells were treated with the PKC inhibitors GF109203X
(Bisindolylmaleimide HCl or GFX, 0.5 to 2 mol/L; Cal- ton Heights, IL, USA). In other experiments, HMCs were
rapidly lysed using an SDS lysis buffer containing 2%biochem-Novabiochem, La Jolla, CA, USA), Ro 32-042
(1 to 10 mol/L; BioMol, Inc., Plymouth Meeting, PA, SDS, 1 mmol/L ethylenediaminetetraacetic acid (EDTA),
1 mmol/L PMSF, 20 mol/L leupeptin, and 0.15 U/mLUSA), or rottlerin (1 to 5 mol/L; BioMol Inc.) at vary-
ing time points (4 to 12 hours) prior to harvest, as we aprotinin. Cell lysates were briefly sonicated at 4C, and
equivalent amounts were promptly separated by 10%have previously described [18]. To determine the role
of ROS in p38 MAPK activation, cells were treated with SDS-PAGE under reducing conditions. After transfer,
the nitrocellulose was probed overnight at 4C with adiamide (2 mmol/L; Sigma) for 10 minutes or H2O2 (100
to 500 mol/L) for 30 minutes. NG and HG cells were rabbit polyclonal anti-phospho-p38 antibody (New En-
gland Biolabs, Beverly, MA, USA). This phospho-specificalso treated with the membrane permeable anti-oxidant
L-N-acetylcysteine (L-NAC, 50 mol/L; Sigma), the fla- antibody was produced by inoculating rabbits with a
peptide fragment representing the tyrosine and threo-voprotein inhibitor diphenyliodonium (DPI, 10 mol/L;
Calbiochem), or the vehicle for DPI, dimethyl sulfoxide nine phosphorylated form of p38 MAPK. In parallel
experiments, HMC lysates obtained by SDS lysis were(DMSO; 0.01%), four hours prior to harvest. Prior to
electrophoretic mobility shift assays (EMSAs), NG and separated by 10% SDS-PAGE under reducing condi-
tions. Following transfer, the nitrocellulose was immu-HG cells were treated for four hours with the p38 MAPK
inhibitor SB 203580 (5 to 15 mol/L; Calbiochem) or noblotted with anti-p38 MAPK antibody (Santa Cruz
Biotechnology), which recognizes phosphorylated and un-with the vehicle of SB 203580, DMSO (0.015%). In some
experiments, we treated cells with interleukin-1 (IL-1; phosphorylated p38 MAPK. Nonimmune rabbit isotype-
specific IgG (Zymed Laboratories) served as control for1.1 ng/mL  30 min, specific activity 5  108 U/mg;
Genzyme, Cambridge, MA, USA), which served as a the primary antibodies.
positive control for p38 MAPK activation.
In vitro p38 MAPK assays
Immunoblotting Human mesangial cells lysed using the HEPES buffer
were clarified and the protein content normalized withConditioned HMCs were washed in PBS, pH 7.4, and
rapidly lysed by scraping in a 4C hypotonic HEPES HEPES lysis buffer without detergent to dilute the NP-40
concentration to0.05%. Thereafter, 2.0g of C-terminusbuffer containing 20 mmol/L HEPES, pH 7.9, 1 mmol/L
Na3VO4, 1 mmol/L egtazic acid (EGTA), 1 mmol/L phe- anti-p38 MAPK antibody (Santa Cruz Biotechnology)
were mixed with the lysate overnight at 4C. The immunenylmethylsulfonyl fluoride (PMSF), 20 mol/L leupep-
tin, and 0.15 U/mL aprotinin, 0.1% NP-40. After clarifi- complexes were precipitated with protein G-Sepharose
and washed three times in cold PBS. The complexes werecation of the lysates, protein content was quantified by
the bicinchinoic method (BCA) using BSA as the stan- then resuspended in a kinase assay buffer containing 20
mmol/L MOPS, pH 7.2, 25 mmol/L -glycerol phosphate,dard (Pierce Analytical Research, Rockford, IL, USA).
One milligram of protein was diluted in HEPES lysis 5 mmol/L EGTA, 1 mmol/L Na3VO4, and 1 mmol/L
dithiothreitol. The measurement of p38 MAPK activitybuffer without detergent, and 2.0 g polyclonal rabbit
anti-p38 MAPK antibody (Santa Cruz Biotechnology, involved a two-step phosphorylation assay (Upstate Bio-
technology). To the immune complex mixture 100mol/LSanta Cruz, CA, USA) were added for overnight immu-
noprecipitation at 4C. Protein G-Sepharose was then adenosine 5	-triphosphate (ATP), 15 mmol/L magne-
sium chloride and 200 ng of the fusion protein GST-added for 45 minutes. The immunoprecipitate was pel-
leted and washed three times in phosphate-buffered sa- MAPKAP kinase-2 were added. The activation of the
MAPKAP kinase-2 by the immunoprecipitated p38 MAPKline (PBS). The proteins were separated by 10% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- was allowed to proceed at 30C for 15 minutes. To this
mixture was then added [
-P32] ATP and 0.12 mmol/LPAGE) under reducing conditions and transferred to 0.45
mol/L nitrocellulose using a semidry technique [51]. Fol- of a peptide sequence that corresponds to residues 1
through 9 of human glycogen synthase. The phosphory-lowing drying, the nitrocellulose was quenched with PBS
0.01% Tween (PBST), 2% BSA for 120 minutes and lation of the peptide fragment by activated MAPKAP
kinase-2 was allowed to proceed at 37C for 10 minutesthereafter immunoblotted with a monoclonal antiphos-
photyrosine antibody (Clone 4G10; Upstate Biotechnol- and was terminated by the placement of the mixture
onto phosphocellulose disks. The disks were allowed toogy Inc., Lake Placid, NY, USA) for 120 minutes at
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air dry for five minutes. They were then washed exten- immunoprecipitated with a polyclonal anti-p38 MAPK
antibody, and the immunocomplexes were separated bysively in 0.75 mol/L phosphoric acid and finally in ace-
tone. Scintillation counting of the disks was performed SDS-PAGE and immunoblotted with an antiphospho-
tyrosine antibody. This antiphosphotyrosine antibody(Beckman Model LS 5801; Beckman Coulter, Inc., Ful-
lerton, CA, USA). was used to determine the specificity of the immunoprec-
ipitating antibody and to determine whether differences
AP-1 electrophoretic mobility shift assay in p38 MAPK tyrosine phosphorylation, a marker of p38
MAPK activation, existed between cell groups. In theseNuclear proteins were harvested from NG and HG
cells, and AP-1 EMSAs were performed as we have experiments, a protein with a molecular mass similar to
p38 MAPK (molecular radius of 39 kD) was stronglydescribed [18, 52]. The cells were washed twice in cold
PBS, pH 7.4, scraped, and centrifuged at 4C. Nuclear tyrosine phosphorylated in the HG cells relative to NG
cells (Fig. 1A). This increased tyrosine phosphorylationprotein extracts were obtained using the protocol of Dig-
nam, Lebovitz, and Roeder as modified by Osborn, Kun- suggested increased p38 MAPK activation. However,
similar to other MAPKs, p38 MAPK is activated whenkel, and Nabel with the addition to each buffer of the
protease inhibitor leupeptin [53, 54]. Protein concentra- dual phosphorylated on tyrosine and threonine residues
[22, 56, 57]. Therefore, using a rabbit polyclonal anti-tions were measured by BCA method (Pierce Analytical
Research) using BSA as the standard. Ten micrograms phospho-threonine/tyrosine p38 MAPK antibody, we
also measured the amount of p38 MAPK dual phosphory-of nuclear protein were added to an incubation buffer
containing 10 mmol/L Tris, 100 mmol/L NaCl, 1 nmol/L lation. These Western blots demonstrated an increase in
the dual phosphorylation of p38 MAPK in HG cells rela-EDTA, 4% glycerol, and 2 mmol/L poly dI-dC. Double-
stranded oligonucleotides containing a tandem repeat of tive to NG cells (Fig. 1B). To verify equal protein loading
of the gels, immunoblots were performed using a rabbitthe classical TPA-responsive element (TRE) and their
complementary strands were annealed and end labeled polyclonal anti-p38 MAPK antibody. No differences in
the amount of total p38 MAPK protein were detectedwith [
-P32] ATP by T4 polynucleotide kinase. Unlabeled
P32-ATP was separated from the oligonucleotide mixture between the treatment groups. Finally, we confirmed an
increase in the kinase activity of p38 MAPK using an inwith D-25 Sephadex columns and 0.2 ng of the labeled
probe was added to the incubation buffer for 20 minutes vitro assay. In these experiments, immunoprecipitated
p38 MAPK proteins were used to phosphorylate theat 27C. The protein–DNA complexes were resolved at
4C on 5% nondenaturing polyacrylamide gels in 0.25  intermediary signaling protein, MAPKAP kinase-2. This
activated MAPKAP kinase-2 then phosphorylated a pep-TBE buffer. Thereafter, the gels were dried and exposed
to autoradiography film at 70C. DNA–protein com- tide substrate that corresponds to the activation domain
of human glycogen synthase, using 32P-ATP as a phos-plexes were demonstrated as bands retarded in their
migration through the gel. Specificity of the bands was phorus source. Results of this kinase assay are demon-
strated in Figure 1C. A basal activation of p38 MAPKconfirmed by incubating the nuclear protein with 50
unlabeled oligonucelotide. activity was apparent in NG cells, which is consistent with
Western blotting that demonstrated a low level of p38
Statistical analyses MAPK phosphorylation. Seven-day HG treatment stim-
ulated p38 MAPK activity to a level 250% above thatThe means  SE of the kinase assays were compared
by the Student t test. Statistical significance was deter- of NG cells. The amount of substrate phosphorylation
(counts per minute mean  SE) was 5986  531 for NGmined by P  0.05.
and 15,618  1720 for HG cells (P  0.01). When time
points earlier than seven days were studied, HG inconsis-
RESULTS
tently activated p38 MAPK, and the level of activation
High glucose concentrations activate p38 MAPK in HMCs was much lower than at seven days.
In these studies, p38 MAPK activation by glucose was
HG activation of HMC p38 MAPK is independent ofmeasured after seven days of HG treatment. The rationale
osmotic stressfor investigating this time point is that at seven days the
phenotype of cultured HMC simulates the phenotype in The p38 MAPK pathway is rapidly inducible by os-
motic stress [24–26, 58], and a role for osmotic activationdiabetic nephropathy. For example, relative to NG-grown
cells, HMCs grown seven days in HG demonstrate lower of p38 MAPK by HG has been shown in rat aortic smooth
muscle cells [14]. We investigated the role of osmoticproliferation rates and increased ECM protein production
[5, 55] and increased activity of transcription factors that stress in p38 MAPK activation using the following exper-
imental approach. First, we measured the activation ofup-regulate ECM genes, such as AP-1 [18]. The activation
of p38 MAPK by HG was assessed using several technical p38 MAPK following a brief exposure of the HMCs to
increasing concentrations of mannitol to determine, inapproaches. First, lysates from conditioned HMC were
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Fig. 2. Large osmotic gradients are necessary for p38 MAPK activation
in HMCs. (A and B) Phospho-p38 MAPK Western blots. HMCs placed
overnight in serum-free media were treated with increasing concentra-
tions of d-mannitol for 30 minutes (A) or with 250 mOsm/L d-mannitol
for 5 to 60 minutes (B). In both blots, treatment of HMCs with IL-1
(1.1 ng/mL  30 min) served as a positive control. Relative to control
(C) levels, d-mannitol (250 mOsm/L) increases phospho-p38 MAPK
Fig. 1. Seven-day high glucose (HG) treatment activates human mes- (p-p38 MAPK) within 15 minutes without changing total p38 MAPK
angial cell (HMC) p38 mitogen-activated protein kinase (MAPK). content (p38 MAPK; N  4). (C) p38 MAPK assays demonstrated in-
HMCs were grown in normal glucose (NG) or HG media for seven creased p38 MAPK activity in cells treated with 250 mOsm/L d-mannitol
days and were harvested as described in the Methods section. (A) Cell relative to control values (C; N 5). *P 0.01. IL-1 treatment stimulated
lysates immunoprecipitated with anti-p38 MAPK antibody (Ab) were p38 MAPK activity threefold above control values. **P  0.001.
separated by SDS-PAGE and immunoblotted with a monoclonal anti-
phosphotyrosine antibody. The tyrosine phosphorylation of p38 MAPK
protein [molecular radius (Mr) 39 kD] was increased in HG lysates
compared to NG (N  3). (B) Lysates harvested with SDS lysis buffer
free media prior to mannitol treatment. As shown inwere separated by SDS-PAGE and immunoblotted with anti-phospho-
threonine/tyrosine-p38 MAPK Ab (p-p38 MAPK) or a polyclonal anti- Figure 2, brief exposures of HMC to increasing concen-
pan-p38 MAPK (p38 MAPK). Dual phosphorylation of a protein with trations of mannitol resulted in up-regulated p38 MAPK
Mr 39 kD (arrow) was greater in HG lysates compared with NG. The phosphorylation only when extremely high concentra-amount of total p38 MAPK did not differ between samples (N  4).
(C) p38 MAPK assays demonstrated increased p38 MAPK activity of tions (250 mOsm/L) were used. The p38 MAPK phos-
HG versus NG cells. The means  SE 32P-cpm of the phosphorylated phorylation induced by mannitol treatment occurred by
peptide are represented. *P  0.01 HG vs. NG (N  8).
15 minutes and persisted for 60 minutes (Fig. 2B). The
kinase activity induced by mannitol paralleled the phos-
phorylation changes. When 250 mOsm/L of mannitol
were used, p38 MAPK activity increased to 155% thata general context, how responsive cultured HMCs are
to osmotic stress. To lessen basal p38 MAPK activity in of control cells (Fig. 2C), a level of activation consider-
ably less than that of IL-1 activation of p38 MAPKthese experiments, cells were placed overnight in serum-
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Fig. 4. Phorbol esters activate HMC p38 MAPK. (A) Phospho-p38
MAPK Western blot. HMCs were placed overnight in serum-free media
(Control) and treated for 30 minutes with increasing concentrations of
PMA. The phospho-p38 MAPK levels (p-p38 MAPK) versus total p38
MAPK content (p38 MAPK) are demonstrated (N 3). (B) p38 MAPK
assay using cell lysates of control and PMA-treated cells (N  4, *P 
0.01).
(IL-1 activation was 315% that of control cells). Second,
we measured the ability of HG media to acutely activate
p38 MAPK. We performed these studies in part to deter-
mine whether acute HG treatment could induce p38
MAPK, even independent of osmotic stress, since in rat
mesangial cells p38 MAPK is inducible following a 60-
minute HG treatment [16]. We investigated p38 MAPK
activation in HMC placed in serum-free media, to de-
crease basal p38 MAPK activity, as well as in serum-
containing media, with the concerns that the HG effects
on HMCs may require the presence of serum compo-
nents [49]. Regardless of the serum content in the media,
Fig. 3. Acute HG treatment and chronic mannitol treatment fail to
acute HG treatment failed to induce changes in p38activate HMC p38 MAPK. (A) Phospho-p38 MAPK Western blot dem-
onstrating the acute effects of HG treatment (hours) on HMC phospho- MAPK phosphorylation in the HMCs (Fig. 3A). Third,
p38 MAPK levels (p-p38 MAPK) relative to total p38 MAPK levels we compared p38 MAPK activation of HMCs grown for(p38 MAPK). Experiments were performed in cells placed overnight
in serum-free media to lower basal p38 MAPK phosphorylation and seven days in NG media with that of cells grown seven
in cells kept in serum-containing media, similar to seven-day treatments days in NG media that was supplemented with mannitol
of HG. IL-1 treatment (1.1 ng/mL 30 min) served as positive controls
at concentrations iso-osmolar to HG media. As shown(N 4). (B) Phospho-p38 MAPK Western using lysates of HMC treated
for seven days in NG media or in media supplemented with d-mannitol in Figure 3 B and C, p38 MAPK dual phosphorylation
at concentrations iso-osmolar to HG media (M; N 4). (C ) p38 MAPK
and kinase activity of cells treated with chronic mannitolassays demonstrated similar levels of p38 MAPK activity in seven-day
NG and seven-day d-mannitol cells (M; N  5). was similar to that of NG cells and less than that of the
HG cells shown in Figure 1. The amount of substrate
phosphorylation (counts per minute mean  SE) was
5986  531 for NG and 4991  873 for the mannitol-
treated cells (87  17% that of NG cell, P  NS).
Wilmer et al: Glucose and p38 MAPK in HMCs864
HG activation of HMC p38 MAPK is
independent of PKC
In some cells, p38 MAPK activity is stimulated by PKC
activation [29–31]. Since HG concentrations activate the
PKC pathway [8, 59], we investigated the role of PKC
in the glucose-mediated p38 MAPK activation. To deter-
mine the responsiveness of HMC p38 MAPK to PKC
activation, cells were treated with the phorbol ester PMA
for 30 minutes. As demonstrated in Figure 4, PMA stimu-
lated a dose-dependent increase in p38 MAPK dual phos-
phorylation and kinase activity. To ensure that this PMA
effect was due to PKC up-regulation, cells were pretreated
for 60 minutes with the specific PKC inhibitors GF 109203
X (GFX) or Ro 32-0432 (Ro) prior to PMA. These PKC
inhibitors were able to inhibit the PMA-mediated activa-
tion of p38 MAPK (Figs. 5A and 6A). Noteworthy is
the fact that the vehicle for Ro 32-0432, DMSO (0.01%),
did not inhibit p38 MAPK activity induced by PMA (Fig.
6A). The down-regulation of p38 MAPK by these PKC
inhibitors occurred in serum-free media as well as serum-
containing media. This was an important observation,
since in parallel sets of experiments GFX and Ro 32-
0432 were added to the NG and HG cells that contained
serum in their media. In this set of experiments, the
inhibitors were added for the last 4 to 12 hours of the
seven-day glucose treatment. GFX and Ro 32-0432, at
concentrations that inhibited the PMA-mediated p38
MAPK phosphorylation, did not inhibit p38 MAPK
phosphorylation in the HG cells (Figs. 5C and 6B).
Since PKC  is activated by HG [60], we investigated
the possibility that glucose-mediated p38 MAPK activa-
tion was due only to PKC  up-regulation. Because the
pan-PKC inhibitors may not inhibit the novel PKC 
isoform as well as they inhibit classic PKC isoforms, cells
also were treated with the PKC  inhibitor rottlerin. No
inhibition of PMA-induced p38 MAPK activation by
rottlerin was observed when concentrations were used
that other investigators have shown is capable of sup-
pressing PKC -mediated activation of p38 MAPK (data
not shown) [61]. This suggests phorbol-ester activation
of p38 MAPK does not require PKC . Similarly, no
inhibition of HG-mediated p38 MAPK phosphorylation
by rottlerin treatment was observed (Fig. 6C).
To ensure these Western blots correlated with p38
MAPK activity, kinase assays were performed. As assessed
by the in vitro kinase assay, p38 MAPK activity induced
by PMA indeed was inhibited by PKC inhibition (Fig.
Fig. 5. GF 109203 X (GFX) inhibits phorbol ester-mediated but not 5B), and similar to the Western blots, PKC inhibition
HG-mediated p38 MAPK activation. The PKC inhibitor GFX (2 did not alter HG-mediated p38 MAPK activity (Fig. 5D).
mol/L  60 min) inhibits p38 MAPK phosphorylation (A) and p38
MAPK activity (B), as assessed by p38 MAPK assays, induced by PMA
treatment (25 nmol/L  30 min). *P 0.02 PMA vs. serum-free control
values; **P 0.01 GFX PMA vs. PMA values (N 3). (C ) Phospho-
p38 MAPK Western blot demonstrating that the addition of GFX (2
lysates. No difference in HG p38 MAPK activity was present whenmol/L) to NG and HG cells for the last 12 hours of treatment did not
GFX (2 mol/L) was added to the HG cells for the last 1to 12 hoursalter the increased p38 MAPK phosphorylation of the HG cells (N 
of treatment (N  5; NS, not significant).4). (D) p38 MAPK assays demonstrated activity of NG () and HG ()
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HG activation of HMC p38 MAPK is
inhibited by antioxidants
The role of oxidant stress in glucose-mediated p38
MAPK activation also was studied. To determine the
ability of ROS to induce p38 MAPK in HMCs, cells
placed overnight in serum-free media were treated with
the cell-permeable compound diamide or with hydrogen
peroxide. We have previously shown these compounds
activate the ERK and JNK pathways in HMC via ROS
generation [62]. As shown in Figure 7A, these oxidants
strongly increased p38 MAPK phosphorylation relative
to the basal activity of control cells. With the evidence
that HMC p38 MAPK can be activated by ROS, the
ability of antioxidants to reverse the glucose-mediated
activation of p38 MAPK was assessed. In these experi-
ments, NG- and HG-conditioned HMCs were treated
with L-NAC or DPI, two compounds that reverse ROS
effects by different routes. These compounds or their
vehicles were added to NG and HG cells for the last
four hours of conditioning. As shown in Figure 7B, inhi-
bition of HG-mediated p38 MAPK activity, but not basal
p38 MAPK phosphorylation of NG cells, was apparent
with the antioxidant treatment. The membrane-perme-
able antioxidant L-NAC decreased the p38 MAPK acti-
vation to a modest extent, and DPI, a potent flavoprotein
inhibitor, strongly reversed the p38 MAPK activation.
As assessed by trypan blue exclusion, these inhibitory
effects of L-NAC and DPI were not due to cell toxicity.
HG activation of HMC p38 MAPK
stimulates AP-1 binding
To determine a relevant effect of p38 MAPK activa-
tion by HG, we assessed AP-1 activation and DNA bind-
ing. AP-1 is a transcription factor complex that regulates
the TGF-1 gene as well as several ECM genes involved
in glomerulosclerosis. We previously reported that HG
environments increase AP-1 binding to DNA promoters
[18]. Curiously, we reported that the HG effect on AP-1
binding was only partially due to PKC activation, since
PKC inhibition did not fully reverse the increased AP-1
Fig. 6. Ro 32-0432 and rottlerin fail to inhibit HG-mediated p38 MAPK binding. We speculated that other mediators of AP-1
activation. The effects of the PKC inhibitors Ro 32-0432 (Ro) and binding might be functional in the HG environment.
rottlerin on p38 MAPK phosphorylation (p-p38 MAPK) were investi-
Therefore, in these current experiments, we hypothe-gated using phospho-p38 MAPK westerns. (A) Relative to serum-free
control levels, PMA (25 nmol/L  30 min) increased p38 MAPK phos- sized that HG-induced AP-1 binding may also occur via
phorylation. Pretreatment (60 min) of cells with Ro (10 mol/L) but not p38 MAPK. AP-1 EMSAs were performed using nuclearthe vehicle for Ro (DMSO) inhibited the PMA-mediated p38 MAPK
proteins from NG and HG cells that had been treatedphosphorylation (N  3). (B) The addition of Ro (10 mol/L) for
the last 12 hours of NG and HG treatment did not alter p38 MAPK for the last four hours of the seven-day glucose treatment
phosphorylation (N  3). NG and HG cells were treated with the
with the p38 MAPK inhibitor SB 203580 or the vehiclevehicle DMSO (0.01%) during Ro treatment. (C ) The addition of
rottlerin (5 mol/L), a PKC  inhibitor, also failed to alter NG- and HG- of SB 203580, DMSO (0.015%). Figure 8 shows a repre-
mediated p38 MAPK phosphorylation. DMSO (0.05%) was present in sentative AP-1 EMSA. AP-1 binding was greater in HG
the NG and HG cells during rottlerin treatment (N  3).
versus NG cells, and treatment with the SB 203580 com-
pound, but not its vehicle, reversed the HG-induced
binding of AP-1.
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Fig. 8. Activator protein (AP-1) activation by HG is attenuated by
p38 MAPK inhibition. Prior to the AP-1 electrophoretic mobility shift
assay (EMSA), NG and HG cells were treated with the vehicle DMSO
(0.015%) or the p38 MAPK inhibitor SB 203580 (15 mol/L) for four
hours prior to nuclear protein harvest. AP-1 EMSAs were performed
as described in the Methods section. The addition of 50 unlabeled
AP-1 oligo to the nuclear proteins served as a competitor. AP-1–specific
bands are demonstrated at the arrow. NS depicts the nonspecific bands
(N  3).
transformation from cells grown in normal glucose in-
volves a series of transcriptional and post-transcriptional
events that follow glucose-mediated activation of cell
signaling pathways. Therefore, identifying these signal-
Fig. 7. Role of reactive oxygen species (ROS) in HG-mediated p38 ing pathways and their targets is critical to the discovery
MAPK activation. (A) The phosphorylation of p38 MAPK (p-p38 of interventions that slow the development of diabetic
MAPK) relative to total p38 MAPK levels (p38 MAPK) was increased
nephropathy. Our studies show that the p38 MAPK path-in serum-free control cells treated for 30 minutes with diamide (2
mmol/L), which increases intracellular ROS, or H2O2 (N  3). (B) The way is an important glucose-responsive pathway in HMCs.
phosphorylation of p38 MAPK was not altered in NG cells treated for Evidence that p38 MAPK is activated in HMCs by HG
the last four hours of the seven-day treatment with L-NAC (NAC, 25
includes the increased tyrosine phosphorylation of p38mol/L) or DPI (10 mol/L; N  3). (C ) The addition of these anti-
oxidants for the last four hours of the seven-day HG treatment signifi- MAPK immunoprecipitated from mesangial cell lysates,
cantly lowered p38 MAPK phosphorylation relative to total p38 MAPK increased dual (tyrosine and threonine) phosphorylation
levels (N  3).
of a protein with molecular mass similar to p38 MAPK,
and increased kinase activity of p38 MAPK immunopre-
cipitated from mesangial cell lysates. These latter experi-
DISCUSSION ments using an in vitro kinase assay demonstrated immuno-
precipitated p38 MAPK is elevated more than twofoldThe phenotype of cultured mesangial cells grown in
HG environments resembles the phenotype of cells in in HMCs grown in HG compared with cells grown in
NG media.diabetic nephropathy [5, 55, 63–66]. Such phenotypic
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Our results corroborate studies that show a glucose- Because the ability of PKC to activate p38 MAPK ap-
pears cell specific, first the ability of phorbol esters tomediated activation of p38 MAPK in VSMCs [14, 17]
and rat mesangial cells [16]. However, our current studies activate p38 MAPK in the HMCs was studied. Treatment
with the phorbol ester PMA strongly activated p38suggest the timing of p38 MAPK activation by glucose
differs between cell type and between culture conditions. MAPK, and this event occurred via PKC up-regulation
since the PKC inhibitors GFX and Ro 32-0432 reversedp38 MAPK induction by glucose in pancreatic islet cells
is rapid and transient [15]. Similarly, Kang et al reported the p38 MAPK activation. Despite these observations,
the glucose-mediated activation of p38 MAPK appearedvery rapid and transient glucose-mediated activation of
p38 MAPK in rat mesangial cells grown on collagen I to be PKC-independent because treatment of HG cells
with these PKC inhibitors did not alter HG-mediatedmatrix prior to glucose treatment [16]. In rat [14] and
porcine [17] VSMCs, p38 MAPK is activated within 24 p38 MAPK activity. Noting that pan-PKC inhibitors may
not fully suppress PKC  isoform activity and HG condi-hours of HG treatment. It is interesting that we were
unable to document such acute activation of the pathway tions can activate PKC  [60], we also used the novel PKC
inhibitor rottlerin, at concentrations shown to inhibit p38in HMCs, and could not consistently demonstrate p38
MAPK activation prior to seven days of glucose treat- MAPK induced via PKC  in other cell systems [61].
Rottlerin treatment failed to inhibit glucose-mediatedment. This difference in the timing of p38 MAPK activa-
tion may be related to intrinsic differences in rate of p38 MAPK activation. Collectively, these observations
suggest that in HMCs, HG induces p38 MAPK indepen-growth of cultured human versus rodent or porcine cells
or to differences in the type of matrix used to culture dently of PKC.
This difference between human and rodent cells mightthe cells.
Differences in the mode of p38 MAPK activation may be explained by cell-specific differences in p38 MAPK
isoform expression. Several p38 MAPK isoforms havealso explain this difference in the timing of activation.
The up-regulation of signaling pathways by HG can be been identified, and their abilities to be activated by
PKC vary [67–71]. What p38 MAPK isoforms are presentgeneralized to those that are direct effects of the HG
environment (for example, osmotic stress) and those that in human and rodent cells and particularly in mesangial
cells remains to be determined. That p38 MAPK is acti-occur through indirect effects regulated by signaling inter-
mediaries, as occurs in PKC activation via diacylglycerol vated in HMCs after several days of HG also suggests
intermediaries such as growth factors that are knownsynthesis. Therefore, we attempted to determine whether
glucose-mediated activation of p38 MAPK occurred via to also activate p38 MAPK [for example, transforming
growth factor-1 (TGF-1), platelet-derived growth fac-a direct osmotic influence or an indirect route. Although
the p38 MAPK pathway is activated by osmotic stress, no tor (PDGF), endothelin] may be responsible. If growth
factors produced in HG environments are the mecha-changes in p38 MAPK activity were observed in HMCs
grown for seven days in mannitol at concentrations that nism of the HG-mediated p38 MAPK activation, an indi-
rect role of PKC may still exist. That is, in these currentwere similar to HG media. This is not surprising since p38
MAPK or JNK activation generally requires extremely studies, a direct PKC activation of p38 MAPK was not
demonstrated; however, an earlier PKC activation byelevated osmotic gradients [24], as we confirmed by dem-
onstrating that p38 MAPK is activated in HMC by man- HG that stimulates growth factor production that then
activates p38 MAPK in a PKC-independent manner maynitol only when very high concentrations are present.
These observations contrast those made in cultured rat be a plausible mechanism. Further study is needed to
determine the role of growth factors in the glucose-medi-VSMCs in which relatively low levels of osmotic stress,
equivalent to a hyperglycemic environment (mannitol ated p38 MAPK activation.
The p38 MAPK pathway is also activated by oxidantconcentrations of 16 mOsm/L), acutely induce the path-
way. Differences by which rat VSMC and HMC sense stress [22, 72]. Several authors have demonstrated that
diabetes or HG states increase oxidant stress [73–78], andand/or protect against osmotic stress, or any other form
of cell stress, may explain these observations. we speculated that the induction of p38 MAPK activity in
HG occurs through changes in the redox potential ofPKC is an intermediary of p38 MAPK activation by
glucose in rat VSMCs [14]. Similarly, Haneda et al dem- HMCs. We demonstrated that diamide and H2O2, potent
stimulators of ROS, could activate p38 MAPK in HMCs.onstrated a PKC-dependent up-regulation of ERK in
cultured murine mesangial cells grown in HG and in We have previously shown these agonists activate the
ERK and JNK pathways in HMCs [62]. When HG cellsglomeruli obtained from diabetic rats [13]. Compared
with p38 MAPK activation in our studies, this ERK were treated with reducing agents for the last several
hours of glucose treatment, p38 MAPK phosphorylationactivation was modest (40% increase in ERK activity
over the NG baseline) but reversible with a six-hour was reduced. The membrane-permeable antioxidant and
thiol reagent L-NAC was able to lessen substantially thetreatment of Calphostin C. We therefore investigated
the role of PKC in the p38 MAPK activation by glucose. glucose-mediated p38 MAPK effects and the flavopro-
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tein inhibitor DPI strongly inhibited p38 MAPK activa- when NG cells were similarly treated or when cells were
treated with the vehicle of SB203580, DMSO. These ob-tion. DPI is a potent inhibitor of NADH/NADPH oxi-
dase [79, 80], and the results of these studies suggest servations strongly argue that a link between p38 MAPK
and AP-1 exists in the HG environment. Such a link wasthese enzymes, which generate H2O2, may be involved
in the altered cell signaling of diabetes. It is noteworthy recently suggested in a study that showed a decline in
TGF-1 production by glucose-conditioned porcine mes-that other authors have recently shown in VSMCs that
DPI and L-NAC reverse p38 MAPK signaling induced angial cells following SB203580 treatment [86]. Given
the absence of JNK activation in HG environments, theby the oxidant stress of PDGF-BB treatment [81]. Fur-
ther work to document the mechanisms of ROS genera- activation of p38 MAPK likely completes TRE gene
expression of bound AP-1. The p38 MAPK pathwaytion in HMCs will be important extensions of these ob-
servations. An important point that needs to be resolved therefore represents an extremely important pathway
through which diabetic nephropathy may evolve.is the difference in ROS sensitivity between the p38
MAPK and JNK pathways, since we previously reported
that the JNK pathway, which also is inducible by oxidant ACKNOWLEDGMENTS
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